Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Single-Use Device Reprocessing Is Safe, Effective, FDA Says At Hearing

This article was originally published in The Gray Sheet

Executive Summary

CDRH Director Daniel Schultz told Congress Sept. 26 that he is confident in the safety of reprocessed single-use devices (SUDs)

You may also be interested in...



Stryker Will Rule Reprocessing Roost With $525 Mil. Ascent Acquisition

Stryker will become the largest medical device reprocessing company in the U.S. with its $525 million acquisition of Ascent Healthcare Solutions, announced Nov. 30

Stryker Will Rule Reprocessing Roost With $525 Mil. Ascent Acquisition

Stryker will become the largest medical device reprocessing company in the U.S. with its $525 million acquisition of Ascent Healthcare Solutions, announced Nov. 30

European Commission Outlines Key Issues In Device Reprocessing Debate

The European Union is taking its first steps towards determining whether to create a uniform policy on the reprocessing of medical devices labeled for single use

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel